Lilly Gets Ready To Compete With Its Late-Stage Diabetes Pipeline
This article was originally published in Pharmaceutical Approvals Monthly
The Indianapolis-based pharma highlighted the Phase III results from two of its most promising pipeline candidates at ADA. The company is preparing to have four new diabetes drugs on the market by 2016, including two basal insulins, a GLP-1 agonist and a SGLT-2 inhibitor.
You may also be interested in...
The Indianapolis-based big pharma touted the value of its late-stage pipeline at an analyst meeting on Oct. 3, particularly its diabetes and oncology franchises, even though they face tough competition and have encountered some setbacks.
Two of the world’s largest pharmaceutical companies are teaming up to develop a treatment for type 2 diabetes, but the drug will have plenty of competitors with a better market position by the time it faces regulatory approval.
J&J is the first pharma company to bring an SGLT2 inhibitor to market, but its window of exclusivity in that class may be narrow, given that FDA is slated to assess two other SGLT2s later this year.